Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Automatic Data Processing

American Electric Power Company

Becton, Dickinson and Co.

Dover

Emerson Electric

Hormel Foods

Mastercard

McDonald's

McCormick

Merck

NIKE

Procter & Gamble

Rockwell Automation

Visa

WestRock

Exxon Mobil

November is about to be a spectacular month of dividend increases. We have 9 expected dividend increases in November, including several Dividend Kings. In this article, we will discuss the 9 companies in detail, along with summarizing some of October's featured dividend increases.

9 Expected Dividend Increases In November 2022

ABIOMED

Johnson & Johnson (JNJ) recently announced it is buying Abiomed for $16.6 billion. These are the details.

Why Johnson & Johnson (JNJ) Is Buying Abiomed For $16.6 Billion

The deal would add heart pumps, a fast-growing part of the medical-device industry, to the J&J lineup.

J&J Agrees to Buy Heart-Device Maker Abiomed for $16.6 Billion

ABIOMED Inc (NASDAQ: ABMD) opened about 50% up on Tuesday after Johnson & Johnson (NYSE: JNJ) said it will buy the heart pump maker for $16.6 billion.

This medical devices stock opened 50% up on Tuesday: here's why

J&J's cardiovascular devices business will benefit from the $16.6 billion deal to acquire Abiomed. The deal comes at a time when J&J is spinning off its consumer health business.

J&J to buy Abiomed in $16.6B deal to boost cardiovascular business

Genuine Parts

Coca-Cola

Stanley Black & Decker

November is here, and also a week that could bring some leftover Halloween tricks instead of treats.

5 Analyst Favorite Dividend Kings to Buy Now That Crushed Q3 Earnings

The pharmaceutical giant will buy the heart-pump maker for $380 a share.

Abiomed Stock Surges on Johnson & Johnson Takeover

Shares of Abiomed Inc. ABMD, -2.32% rocketed 48.8% toward a 14-month high in premarket trading Tuesday, after the provider of medical technology that supports circulation and oxygenation agreed to acquired by Johnson & Johnson JNJ, -0.51% in a deal valued at $16.6 billion. Under terms of the deal, J&J will pay upfront $380 in cash for each Abiomed share outstanding, which represents a 50.7% premium to Monday's closing price of $252.08.

Abiomed stock rockets after J&J buyout deal valued at $16.6 billion

Johnson & Johnson said on Tuesday it will buy heart pump maker Abiomed Inc in a deal valued at $16.6 billion to boost its cardiovascular devices business.

J&J to buy heart pump maker Abiomed in $16.6 bln deal

Johnson & Johnson to Acquire Abiomed

Apple

Broadcom

Pfizer

UnitedHealth Group

The beautiful thing about cash-rich companies is not just that they perform well. Yes, their prices often rise exactly because their profits allow for the stockpiling of cash.

7 Cash-Rich Dividend Stocks to Buy Now

Accenture Plc

Cisco Systems

Home Depot

Microsoft

Starbucks

Alphabet

When it comes to investing, most of us are looking for predictable growth over the long term with minimal effort and some measure of security. That's what blue-chip stocks typically provide.

7 Blue-Chip Stocks Set to Soar From 52-Week Lows

ESSA Pharma

Shares of Essa Pharma Inc. EPIX, +1.38% fell 28.6% in premarket trading on Monday after the company said Johnson & Johnson JNJ, +1.49% suspended enrollment in a Phase 1 clinical trial for Essa's experimental prostate cancer therapy, citing patient recruitment challenges. Essa had announced a clinical collaboration with J&J back in 2021.

J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Oct. 31, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that Janssen Research and Development ("Janssen") is suspending enrollment into the Phase 1 clinical study of EPI-7386 with apalutamide or EPI-7386 with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer ("mCRPC") patients as a result of operational recruitment challenges.   Before suspending enrollment, Janssen treated three mCRPC patients (pre-chemotherapy) with the combination of EPI-7386 and apalutamide or abiraterone acetate plus prednisone for up to four months of therapy.

ESSA Provides an Update on its Clinical Collaboration with Janssen

Johnson & Johnson's corporate history can be traced back to the late 19th century.

Buy This Dividend King for 2022 and Beyond

McKesson

With fears of a recession rising, two of the three are already outperforming the S&P 500.

3 Warren Buffett Stocks That Should Beat the Market During a Recession

Johnson & Johnson has solidified its market leadership position over the years. The company tends to outperform the market during economic crises, and its operations are less vulnerable to recessions.

Johnson & Johnson: Attractive Opportunity During Market Turmoil

Colgate-Palmolive

There aren't many companies that have dividend growth streaks more impressive than these two stocks.

Got $1,000? These 2 Dividend Kings Are Trading Near Their 52-Week Lows

Intuitive Surgical

Stryker

As surgeries bounce back toward pre-pandemic levels, these three companies should benefit.

3 Medical Stocks On the Rebound

Amazon

Blackrock Inc

iShares Core S&P 500 ETF

ProShares Short S&P500

SPDR S&P 500 ETF Trust

A fund that invests in the companies in the S&P 500 can be a great way to start a portfolio and invest for the long term.

News for Johnson & Johnson Stock (JNJ)